Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 5/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.38 |
| ▸ | ACE | P12821 | 3/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.33 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16417915 | 0.88 | ACE (0.34) | ACEGPR84FFAR1ZDHHC7MAPT | |
| SCHEMBL12352384 | 0.87 | ARG1 (0.34) | ACEGPR84FFAR1ZDHHC7MAPT | |
| SCHEMBL23049524 | 0.85 | ACE (0.32) | ACEGPR84FFAR1ZDHHC7MAPT | |
| SCHEMBL10290922 | 0.85 | MMP3 (0.40) | MMP3MMP9ACEFFAR1MAPT | |
| SCHEMBL16417920 | 0.83 | CA1 (0.44) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL10290409 | 0.82 | EPHX1 (0.38) | MMP3MMP9ACEGPR84FFAR1 | |
| SCHEMBL22294273 | 0.81 | CA1 (0.46) | GPR84FFAR1MAPT | |
| SCHEMBL12352194 | 0.81 | CA1 (0.46) | GPR84FFAR1MAPT | |
| SCHEMBL10290154 | 0.80 | L3MBTL1 (0.42) | MMP3MMP9ACEGPR84FFAR1 | |
| SCHEMBL10290342 | 0.79 | MMP3 (0.39) | MMP3MMP9ACEGPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | MMP3 161/4885MMP9 175/4885ACE 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.